Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
07/2003
07/02/2003CN1427826A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use
07/02/2003CN1427824A Indole derivatives, process for preparation of same and use thereof
07/02/2003CN1427725A Casein derived peptides and uses thereof in therapy
07/02/2003CN1426787A Health care mixture for antifatigne and enhancing immunity
07/02/2003CN1113059C Pipeazino derivatives as neurokinin antagonists
07/02/2003CN1113057C Quinoline derivatives
07/02/2003CN1112927C Pharmaceutical composition of corpus albicans emulsifier type lipophilic compound
07/01/2003US6586578 Deformylase (def1); isolated polynucleotide of given sequence; detects Staphylococcus aureus; can use to screen for antibiotics
07/01/2003US6586474 Amidino compounds useful as nitric oxide synthase inhibitors
07/01/2003US6586456 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide
07/01/2003US6586446 Chemotaxic cytokine agonists or antagonists such as N(3-acetylphlenyl)-N'-(-2-((-3-((4-fluorophenyl)methyl)-8 -azabicyclo(3.2.1)oct-8-yl)methyl)-(2R)-1-cyclohexyl)urea, used as antiinflammatory agents for asthma or allergies
07/01/2003US6586445 Racemic mixtures of 1,2,3,4-tetra hydro-1-(4-methoxyphenyl)-3 -(4-phenyl-1H-imidazol-2-yl)-9H- pyrido(3,4-b)indole, which bind to somatostatin receptors and block sodium channel modulators; antidiabetic, antiinflammatory agents; diarrhea
07/01/2003US6586441 Adenosine receptor ligands and their use in the treatment of disease
07/01/2003US6586432 Neurokinin-1 receptor antagonists
07/01/2003US6586431 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives
07/01/2003US6586429 For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders
07/01/2003US6586424 Anticancer agents; anticholesterol agents
07/01/2003US6586423 Tyrosine kinase inhibitors
07/01/2003US6586400 Human therapeutic uses of BPI protein products
07/01/2003US6586242 TAO protein kinases and methods of use therefor
07/01/2003US6586015 Use of Phyllanthus for treating chronic inflammatory and fibrotic processes
07/01/2003US6585997 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
07/01/2003US6585973 Solid phase adjuvant methodology is used to synthesize a hapten-protein-polysaccharide conjugate vaccines to stimulate an anti- polysaccharide antibody response in infants who are otherwise unable to respond to polysaccharide alone
07/01/2003US6585958 Medicinal aerosol formulations
07/01/2003CA2123303C Icams immunoglobulin constant region soluble fusion proteins
07/01/2003CA2086509C Non-cleavable soluble hybrid gp160 variant
06/2003
06/26/2003WO2003052414A1 Screening method
06/26/2003WO2003052106A1 Method of screening compounds
06/26/2003WO2003052089A1 Disruption of the glutathione s-transferase-omega-1 gene
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051923A2 Novel g-protein coupled receptors and dna sequences thereof
06/26/2003WO2003051922A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
06/26/2003WO2003051921A1 Chemokine mutants acting as chemokine antagonists
06/26/2003WO2003051893A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051888A1 6-aminomorphinane derivatives, method for the production and use thereof
06/26/2003WO2003051884A1 Fused indole compound, process for producing the same, and use
06/26/2003WO2003051872A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists
06/26/2003WO2003051869A1 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
06/26/2003WO2003051868A1 Lactams as tachykinin antagonists
06/26/2003WO2003051864A1 Isoflavonoid conjugates, compositions thereof and therapeutic methods involving same
06/26/2003WO2003051851A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003WO2003051828A2 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
06/26/2003WO2003051819A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003WO2003051807A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051454A2 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
06/26/2003WO2003051393A2 Enzymatic cleavable reagents for specific delivery to disease sites
06/26/2003WO2003051388A2 Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
06/26/2003WO2003051385A1 Pharmaceutical formulation comprising cyclosporin and use thereof
06/26/2003WO2003051365A2 Use of compounds of the benzamide family as immunosuppressant
06/26/2003WO2003051361A1 Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
06/26/2003WO2003051358A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003WO2003051305A2 Innate immune system-directed vaccines
06/26/2003WO2003051277A2 Novel compounds
06/26/2003WO2002094860A3 Dimerized t-cell receptor fragment, its compositions and use
06/26/2003WO2002094202A3 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
06/26/2003WO2002046385A3 Enzymes
06/26/2003WO2002016597A3 Lipid metabolism enzymes
06/26/2003US20030121065 Polyfunctional base sequence and artificial gene containing the same
06/26/2003US20030120080 Such as (2S)-2-((4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl) butanamide; antiepileptic agents; anticonvulsants
06/26/2003US20030120079 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction
06/26/2003US20030120076 Vitreous form
06/26/2003US20030120071 Chemical compounds
06/26/2003US20030120059 Cell surface molecule-induced macrophage activation
06/26/2003US20030119881 Antivirals
06/26/2003US20030119878 A 1-arylalkyl-3-aminoalkyl-1,4-dihydropyrid-4-one derivative; sexual disorders; anticarcinogenic agents; benign prostatic hypertrophy/fibroids of the uterus; endometriosis, polycystic ovarian disease, precocious puberty; contraceptives
06/26/2003US20030119877 Pyridine derivatives useful as cyclooxygenase inhibitor
06/26/2003US20030119869 1-(Piperidin-4-yl)benzimidazole or -triazole derivatives; agonists and antagonist for beta-chemokine (chemotactic cytokines) receptors; viricides; HIV; antiarthritic agents; atherosclerosis, psoriasis, antiallergens; multiple sclerosis
06/26/2003US20030119853 Thiocarboxamide derivatives
06/26/2003US20030119847 Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1
06/26/2003US20030119838 Water-soluble phenylpyridazine compounds and compositions containing the same
06/26/2003US20030119835 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
06/26/2003US20030119830 Monocyte chemoattractant protein-1 inhibitor compounds
06/26/2003US20030119829 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of PDE7B-mediated diseases and conditions
06/26/2003US20030119827 Peptidyl carbamates; treatments for osteoporosis and autoimmune diseases
06/26/2003US20030119820 Substituted indoles
06/26/2003US20030119797 Methods for selective immunomodulation
06/26/2003US20030119788 N-cyanomethyl carbonamides and sulfonamides which are cysteine protease, particularly cathepsin K, inhibitors
06/26/2003US20030119786 Combinations for the treatment of immunoinflammatory disorders
06/26/2003US20030119780 Therapeutical treatments
06/26/2003US20030119773 Method for enhancing an immune response
06/26/2003US20030119748 Use for treatment of inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury.
06/26/2003US20030119715 Prevent retinoid binding; antiaging agents; activation cell differentiation
06/26/2003US20030119182 Immunotherapy; genetic engineering; anticancer agents
06/26/2003US20030119149 Fusion protein capable of forming a trimer; nonimmunogenic; modulates signaling of tumor necrosis family receptors
06/26/2003US20030119148 Amino-terminally truncated rantes as chemokine antagonists
06/26/2003US20030119111 G-protein coupled receptor, named 2871 receptor
06/26/2003US20030119095 Novel nucleic acid sequences encoding human vesicle transport protein-like and residue rat-like polypeptides
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030119070 Complexing ligand, peptide ; displacement of one ligand with another
06/26/2003US20030119045 Controlling cell proliferation; adjust adhesion to substrate
06/26/2003US20030118659 Antigen-specific induction of peripheral immune tolerance
06/26/2003US20030118648 Two combined tablet portions, with different releasing rates; drug delivery providing immediate, sustained and prolonged release
06/26/2003US20030118602 Peptides and immunologically functional variants thereof which are immunogenic epitopes recognized by CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus infection
06/26/2003US20030118600 Transfer compounds, production and use thereof
06/26/2003US20030118594 Stable formulations of mhc-peptide complexes
06/26/2003US20030118575 Administering a pyrazole compound containing urea or thiourea groups, twice daily to a patient in need of treatment of a cytokine mediated disease
06/26/2003US20030118564 Intra-tumoral administration of il-12 encoding nucleic acid molecules
06/26/2003US20030118528 Topical delivery of codrugs
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003CA2471500A1 Substituted 1,5-diaminopentan-3-ol compounds
1 ... 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 ... 1172